Sign in
CompletedPhase 2

Ibogaine in the Treatment of Alcoholism: an Open-label Escalating-dose Trial

Key facts

Who runs it
University of Sao Paulo
Where
Brazil1 site in 1 countryChoose a country to see its sites
Trial code
Status
Completed
Phase
Phase 2
People taking part
9 people enrolled
Started
30 Oct 2022
Ended
30 Oct 2024
Type of study
Interventional
Treatments tested
  • Ibogaine Hydrochloride
Record updated
26 November 2024

Who can take part

Age
18 years to 65 years
Sex
Women and men
Healthy volunteers
Cannot take part

The registry criteria, word for word

Show all 11 criteriaShow less

Who can take part

  • Literate people
  • Diagnosis of alcoholism assessed by the Structured Clinical Interview for Diagnostic and Statistical Manual of Mental Disorders (SCID-V)
  • History of at least two previous failed treatments for alcoholism (with drug use and / or psychotherapy)
  • Signing the Free and Informed Consent Form

Who cannot take part

  • Recent use of illicit drugs (confirmed by examination in urine)
  • Presence of any psychiatric diagnosis (excluding alcohol / tobacco / nicotine abuse / dependence) assessed by the SCID-V
  • Absence of family or personal history of bipolar disorder and psychotic disorders
  • Presence of clinical disease (especially cardiovascular and hepatic diseases), based on interview, physical and laboratory examination (hemogram and electrocardiogram, ECG)
  • Absence of recent symptoms of hypomania, mania or psychosis
  • Non-literate people
  • Pregnant or lactating women

Where is this trial?

It has sites in one country. Choose a country to see its sites.

About the trial

What the trial wants to find out

Approximately 5% of the world's adult population has some alcohol-related disorder, which in addition is associated with 3% of all deaths in the world. In Brazil, harmful use and dependence on alcohol reach about 10% of the population, with alcohol being one of the main factors of disease and mortality. Although the medications currently used have some efficacy, the adverse effects and relatively long time of treatment are factors that may reduce patients' motivation to continue taking the medication correctly. Therefore, it is necessary to conduct research with new drugs for the treatment of alcoholism. Ibogaine is an alkaloid present in the bush Tabernanthe iboga (iboga), a plant from Central Africa traditionally used in countries such as Gabon and Cameroon. Animal studies and case series suggest that one or a few doses of ibogaine significantly reduce withdrawal symptoms and the intensity of use of various drugs, including opioids, psychostimulants, and alcohol. However, there are no controlled clinical studies that have explored these effects. The aim of the present study is to evaluate the safety, tolerability and efficacy of increasing doses of ibogaine in 12 alcoholic patients. Each patient will be hospitalized for 20 days and receive 3 increasing doses of ibogaine. The first 3 patients will receive oral doses of 20 to 400 mg of ibogaine in an open-label design. If the 3 higher doses (240, 320 and 400 mg) are well tolerated, the next 9 volunteers will receive these doses or placebo randomly. The volunteers will also be evaluated 7, 14 and 21 days and 1, 3, 6 and 12 months after leaving the hospital to monitor the consumption of alcohol and other drugs.

The group in the trial

  • IbogaineTreatment being tested

    Ibogaine Hydrochloride 240 mg on day 1, placebo on day 4, placebo on day 7

    Treatment: Ibogaine Hydrochloride

Data and sources

Registry record
Listed on ClinicalTrials.gov.How to verify a trial in the registry
Official title
Tolerability and Efficacy of Ibogaine in the Treatment of Alcoholism: an Open-label Escalating-dose Trial
Record updated
26 November 2024